Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Invested Capital (2020 - 2026)

Cytek Biosciences filings provide 6 years of Invested Capital readings, the most recent being $342.3 million for Q4 2025.

  • On a quarterly basis, Invested Capital fell 13.74% to $342.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $342.3 million, a 13.74% decrease, with the full-year FY2025 number at $342.3 million, down 13.74% from a year prior.
  • Invested Capital hit $342.3 million in Q4 2025 for Cytek Biosciences, down from $379.2 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $427.8 million in Q4 2022 to a low of -$11.0 million in Q2 2021.
  • Median Invested Capital over the past 5 years was $395.7 million (2023), compared with a mean of $358.7 million.
  • Biggest five-year swings in Invested Capital: soared 40644.2% in 2022 and later decreased 13.74% in 2025.
  • Cytek Biosciences' Invested Capital stood at $405.4 million in 2021, then increased by 5.53% to $427.8 million in 2022, then dropped by 7.74% to $394.7 million in 2023, then rose by 0.53% to $396.8 million in 2024, then decreased by 13.74% to $342.3 million in 2025.
  • The last three reported values for Invested Capital were $342.3 million (Q4 2025), $379.2 million (Q3 2025), and $378.3 million (Q2 2025) per Business Quant data.